Redefining shared decision-making in the digital era

Publication date: Available online 20 July 2019Source: European Journal of Surgical OncologyAuthor(s): Nikhil Panda, Ian Solsky, Alex B. HaynesAbstractPerioperative shared decision-making can be improved through the development of novel patient-centered outcome measures made possible by digital phenotyping—“the moment-by-moment quantification of individual-level human phenotype in situ using data from personal digital devices, in particular smartphones.” This Short Report presents data from a patient with breast cancer that illustrates the opportunities of digital phenotyping to better inform patient quality of life while also discussing the challenges to its adoption. With time, effort, and physician engagement, digital phenotyping can help surgeons better understand the patient experience in the postoperative period and in turn, help them provide care that maximizes patient quality of life.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research

Related Links:

Authors: Md Pauzi SH, Saari HN, Roslan MR, Syed Khair Azman Jamalulil SNS, Tauan IS, Mohd Rusli FA, Aizuddin AN Abstract INTRODUCTION: Evaluation of HER2 status in breast cancer using immunohistochemistry (IHC) and in-situ-hybridisation (ISH) study is important to establish prognosis and to select patient for targeted therapy. OBJECTIVE: The study aims to determine the concordance between HER2 protein IHC score and its gene status by dual-colour dual-hapten in-situ-hybridization (DDISH) study. MATERIALS AND METHODS: Retrospective study was performed on 767 referred breast cancer cases over a period of five ...
Source: Malaysian Journal of Pathology - Category: Pathology Tags: Malays J Pathol Source Type: research
Publication date: Available online 20 August 2019Source: Academic RadiologyAuthor(s): Laura Heacock, Alana Lewin, Abimbola Ayoola, Melanie Moccaldi, James S. Babb, Sungheon G. Kim, Linda MoyRationale and ObjectivesPathologic complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after HER2-targeted therapy correlates increased disease-free survival and decreased mastectomy rates. The aim of this study was to explore tumor shrinkage patterns and initial tumor enhancement with pCR in HER2-positive breast cancer.Materials and MethodsThis was an institutional review boar...
Source: Academic Radiology - Category: Radiology Source Type: research
This study assessed the inter-observer agreement of histological grading in a series of ILBC and LN.54 cases (36x ILBC, 18x LN) were evaluated by 17 observers. 3978 classification calls on various histological features, including nuclear grade, proliferative activity (Ki67 immunohistochemistry, categorical scoring), histological grade and pleomorphism were obtained. Pairwise Cohen’s kappa values were calculated and compared between various features and different observer subsets with variable histomorphological experience.In ILBC, pairwise inter-observer agreement for histological grade ranged from poor to almost per...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Broader recommendations on screening for BRCA1/2 genetic mutations published...Read more on AuntMinnie.comRelated Reading: Men need breast cancer screening too MRI finds breast cancer early in women with family history PET tracers help guide breast cancer therapies Breast cancer mutation increases interval cancer risk Screening breast MRI alone OK for high-risk women
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Introduction: Endocrine therapies (ETs) are associated with alopecia (EIA) in 15-25% of patients. There are no approved therapies for EIA. The purpose of this review is to provide dermatologists and oncologists with a foundation for the practical understanding of 5 α-reductase inhibitors and spironolactone for breast cancer patients and survivors with alopecia attributed to ETs, including the effect of these treatments on sex hormone levels, any reported drug interactions, and any risk of malignancy.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Although rare, cutaneous metastases may be the initial presentation of an undetected primary malignancy. Among internal malignancies, breast carcinoma is the most frequent solid tumor to cause cutaneous metastases, occurring in a small minority of breast cancer patients, at a rate of approximately 2.5% per primary tumor. Clinically, the manifestations of cutaneous metastatic breast cancer can vary and may be quite subtle. This may include solitary or multiple skin papules, nodules with cutaneous discoloration or textural changes, and can mimic benign skin lesions.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
We report a case of exemestane induced pseudocellulitis.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Introduction: Patients diagnosed with breast cancer may be at an increased risk for second primary malignant melanoma (SPCMM). The study aim was to determine the risk for SPCMM in those with known breast cancer receptor status: estrogen, ER(+) or ER(-), progesterone, PR(+) or PR(-), using the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Background: Persistent hair disorders resulting from cytotoxic or endocrine agents used in early stages of breast cancer such as alopecia, hirsutism, and madarosis develop in 4-35% of patients, however their impact on quality of life (QoL) has not been reported. The CHANCE study is a prospective, longitudinal study of chemotherapy- and endocrine therapy-induced hair, skin, and nail changes in women with nonmetastatic breast cancer. This preliminary analysis intends to evaluate the impact of permanent hair sequelae of adjuvant breast cancer therapies on patients ’ QoL.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Conditions:   Breast Cancer;   Solid Tumor Intervention:   Drug: OBT076, a CD205-directed antibody-drug conjugate Sponsor:   Oxford BioTherapeutics Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Surgery